Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian @entity35 by the XXXX inactivator PFT-a.

@entity10740 @entity669 @entity12559 @entity935 @entity191 @entity3826 @entity35 @entity717 @entity2955
A key limiting factor impacting the success of cell transplantation for @entity191 is the survival of the grafted cells, which are often short lived. The focus of this study was to examine a novel strategy to optimize the survival of exogenous fetal ventromesencephalic (VM) grafts by treatment with the @entity10740 inhibitor, @entity12559 -a (PFT-a), to improve the biological outcome of @entity191 animals. Adult male @entity35 were given @entity2955 into the left medial forebrain bundle to induce a hemiparkinsonian state. At 7 weeks after lesioning, animals were grafted with fetal VM or cortical tissue into the lesioned striatum and, thereafter, received daily PFT-a or vehicle injections for 5 days. @entity3826 -induced @entity717 was examined at 2, 6, 9, and 12 weeks after grafting. Analysis of TUNEL or @entity669 hydroxylase (TH) immunostaining was undertaken at 5 days or 4 months after grafting. The transplantation of fetal VM tissue into the lesioned striatum reduced @entity717 . A further reduction in rotation was apparent in animals receiving PFT-a and VM transplants. By contrast, no significant reduction in rotation was evident in animals receiving cortical grafts or cortical grafts + PFT-a. PFT-a treatment reduced TUNEL labeling and increased TH(+) cell and fiber density in the VM transplants. In conclusion, our data indicate that early postgrafting treatment with PFT-a enhances the survival of @entity935 cell transplants and augments behavioral recovery in @entity191 animals.
